NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Forecast & News

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) released its earnings results on Thursday, November, 7th. The company reported $0.56 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.58 by $0.02. The business had revenue of $4.26 billion for the quarter, compared to analysts' expectations of $4.25 billion. Teva Pharmaceutical Industries had a positive return on equity of 15.41% and a negative net margin of 22.88%. View Teva Pharmaceutical Industries' Earnings History.

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Wednesday, February 12th 2020. View Earnings Estimates for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, February 12th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Teva Pharmaceutical Industries issued an update on its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of $2.30-2.50 for the period, compared to the Thomson Reuters consensus estimate of $2.38. The company issued revenue guidance of $$17.2-17.4 billion, compared to the consensus revenue estimate of $$17.18 billion.

23 Wall Street analysts have issued 12-month price objectives for Teva Pharmaceutical Industries' shares. Their forecasts range from $6.00 to $20.00. On average, they expect Teva Pharmaceutical Industries' stock price to reach $10.48 in the next twelve months. This suggests a possible upside of 3.8% from the stock's current price. View Analyst Price Targets for Teva Pharmaceutical Industries.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 13 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Teva Pharmaceutical Industries.

Media headlines about TEVA stock have been trending somewhat negative this week, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Teva Pharmaceutical Industries earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Teva Pharmaceutical Industries.

Some companies that are related to Teva Pharmaceutical Industries include Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), UCB (UCBJF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL) and Beigene (BGNE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Intel (INTC), Bank of America (BAC), Gilead Sciences (GILD), Advanced Micro Devices (AMD) and Cisco Systems (CSCO).

Teva Pharmaceutical Industries' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Commerzbank Aktiengesellschaft FI (0.72%), Harel Insurance Investments & Financial Services Ltd. (0.49%), Personal Resources Investment & Strategic Management Inc. (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), Financial Sense Advisors Inc. (0.02%) and Usca Ria LLC (0.01%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Iris Beck Codner, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Roberto Mignone, Sol J Barer and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.

TEVA stock was sold by a variety of institutional investors in the last quarter, including Commerzbank Aktiengesellschaft FI, Zurcher Kantonalbank Zurich Cantonalbank , Usca Ria LLC, Janney Montgomery Scott LLC, Cacti Asset Management LLC, Hanson & Doremus Investment Management, Heritage Investors Management Corp and Argyle Capital Management Inc.. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Hafrun Fridriksdottir, Luzich Partners Llc, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

TEVA stock was purchased by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., Financial Sense Advisors Inc., Moon Capital Management LLC, Personal Resources Investment & Strategic Management Inc., DNB Asset Management AS, Wedbush Securities Inc., Eqis Capital Management Inc. and Sumitomo Mitsui DS Asset Management Company Ltd. Company insiders that have bought Teva Pharmaceutical Industries stock in the last two years include Roberto Mignone, Sol J Barer and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TEVA stock can currently be purchased for approximately $10.10.

Teva Pharmaceutical Industries has a market capitalization of $11.02 billion and generates $18.85 billion in revenue each year. The company earns $-2,150,000,000.00 in net income (profit) each year or $2.80 on an earnings per share basis. Teva Pharmaceutical Industries employs 42,535 workers across the globe.View Additional Information About Teva Pharmaceutical Industries.

The official website for Teva Pharmaceutical Industries is http://www.tevapharm.com/.

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]